Measuring Sleep Disturbance Among Cancer Patients
Public ClinicalTrials.gov record NCT00505544. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
The Brief Sleep Disturbance Scale: Measuring Sleep Disturbance Among Cancer Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Objectives: Primary Objectives: 1. To establish concurrent criterion-related validity of the Brief Sleep Disturbance Scale (BSDS) by correlating the scale with the Pittsburgh Sleep Quality Index. 2. To evaluate the construct validity of the BSDS through exploratory factor analysis. 3. To examine possible predictors of sleep disturbance. 4. To evaluate the reliability of the BSDS using Cronbach's coefficient alpha and test-retest reliability. 5. To evaluate the sensitivity of the BSDS by administering it to the same group of patients (n = 60) prior to treatment with a regimen associated with sleep disturbance, during 4 weeks of treatment, and upon completion of treatment. 6. To evaluate the psychometric properties of the BSDS in a sample of community dwelling adults. Secondary Objective: 1\. To obtain pilot data from a small sample of patients who will wear an actigraph for one week.
Study identification
- NCT ID
- NCT00505544
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 459 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2005
- Primary completion
- Jul 10, 2022
- Completion
- Jul 10, 2022
- Last update posted
- Jul 12, 2022
2005 – 2022
United States locations
- U.S. sites
- 2
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Lyndon Baines Johnson General Hospital | Houston | Texas | 77030 | — |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00505544, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 12, 2022 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00505544 live on ClinicalTrials.gov.